Searchable abstracts of presentations at key conferences in endocrinology

ea0056gp95 | Diabetes Therapy | ECE2018

Randomized control study to compare security and efficacy of the new long acting analogues degludec and glargina U300 in people with type 1 Diabetes. Preliminary results of the Ineox study

Dominguez-Lopez Marta Elena , Vallejo Rosario , Morillas Virginia , Colomo Natalia , Guerrero Mercedes , Rojo Gema , de Adana Navas Marisol Ruiz

Background: There aren’t published randomized studies comparing the clinical impact of degludec and Glragina U300 in the treatment of type 1 diabetes patients. (T1DP)Objective: To compare efficacy and safety of the new long acting analogues Glargine U 300 and Degludec in 300 Type1 diabetes patients treated with basal/bolus treatment.(BBT)Material and methods: Randomized control study 1.1 in 300 T1DP treated with BBT with glarg...

ea0032p366 | Diabetes | ECE2013

Clinical experience of a monogenic diabetes unit during 2008–2012 in the Department of Endocrinology and Nutrition (Malaga, Spain)

Dominguez-Lopez Marta , Fernandez-Arias J David , Gonzalez-Molero INmaculada , Valdes Sergio , Miguel Gomez-Zumaquero Juan , Guerrero Mercedes , Colomo Natalia , Omiste Antonio , Palau David , Soledad Ruiz de Adana Maria , Escofet Federico Soriguer

Objectives: MODY diabetes is the most common form of monogenic diabetes, encompassing a heterogeneous group of disorders whose primary defect results from mutations in one of at least seven genes recognized, associated with a primary defect in insulin secretion. It has early onset and autosomal dominant inheritance.Our objective was to evaluate the results of monogenic diabetes clinic of the Endocrinology and Nutrition Department during 2008–2012.</...